RNF43 variants carry colorectal cancer risk, but the phenotype is less fixed than first described
The inherited RNF43 story is more complicated than a tidy syndrome of early colorectal cancer and obvious serrated polyposis. In a large analysis spanning nearly 50,000 colorectal cancer and polyp cases, the gene remained a bona fide predisposition locus, yet the clinical picture was often far less dramatic than the family-based reports that first brought it to attention. Many carriers did not have multiple polyps, and several lacked a striking family history. Some tumors even appeared to arise independently of the germline variant, a reminder that a predisposition gene can raise risk without dictating a single, uniform disease pattern.
One family in the CORGI cohort still fit the classic model: a multigenerational pedigree with early-onset colorectal cancer and serrated and/or filiform polyps, carrying a germline loss-of-function RNF43 variant, p.Thr158ProfsTer6. The broader population, however, looked different. Among participants in the 100,000 Genomes Project and UK Biobank, germline RNF43 mutations appeared in both cases and controls, and the expected polyp burden was often absent. That separation between genotype and overt phenotype has immediate implications for counseling, surveillance, and how much weight clinicians should place on a single positive result when the colonoscopic picture is otherwise quiet.
Risk is real, but not evenly distributed across the gene
Case-control analysis linked germline RNF43 variants to colorectal cancer risk, with an odds ratio of 2.696 and a p value of 0.010. The signal is meaningful, but it does not support an assumption of uniformly high penetrance across all carriers. Risk clustered much more strongly in the N-terminal half of the gene, where germline variants had greater clinical impact. By contrast, germline C-terminal mutations did not confer increased colorectal cancer risk in this dataset.
That difference matters biologically. RNF43 is a negative regulator of Wnt signaling, and the location of a truncating or loss-of-function event can shape how much residual protein function remains. N-terminal disruption is more likely to disrupt core protein architecture early, while C-terminal changes may leave enough activity in place to blunt phenotype in some carriers. The data do not prove a single mechanism for every variant, but they do argue against treating all germline RNF43 alterations as interchangeable when risk stratifying families.
Somatic RNF43 changes behave differently from inherited variants
A separate pattern emerged in the tumor sequencing work. Among 2,722 colorectal cancers, somatic RNF43 mutations in the C-terminal region were pathogenic even though the parallel germline C-terminal variants were not associated with excess cancer risk. The most plausible explanation is cooperative genetics: somatic C-terminal RNF43 alterations may exert weaker effects on their own, but those effects are amplified when the same tumor also carries additional Wnt-pathway changes.
This is the biology of colorectal tumorigenesis in action. A single lesion in a Wnt regulator does not need to do all the work if the tumor can recruit other pathway hits to push signaling over the threshold for clonal expansion. The study identified accompanying mutations in Wnt genes, including ZNRF3, and also implicated a new driver, SFRP4. In practical terms, inherited and acquired RNF43 defects cannot be interpreted through the same lens. Germline variants inform predisposition; somatic variants describe tumor evolution.
Phenocopies complicate genetic counseling
The presence of CRC or polyp disease in an RNF43 carrier does not always mean the inherited variant is the direct cause of that individual tumor. Some cancers developed independently of the germline mutation, which creates a molecular phenocopy problem: the same clinical endpoint can arise through different genetic routes, even in someone who already carries a plausible predisposition allele. For clinicians, that complicates family counseling and pathogenicity assessment. A carrier with few or no polyps may still be at increased risk, but a positive result should not be treated as a complete explanation for every lesion found in the bowel.
The reverse is also true. A patient with colorectal cancer and an RNF43 variant may not fit the stereotyped serrated polyposis picture. That should not dilute the importance of the finding; it should sharpen it. Genetic testing strategies that assume a single, highly penetrant syndrome risk missing the spectrum actually seen in population-scale data. The study makes clear that the old image of RNF43 as a monolithic polyposis gene is too narrow for real-world practice.
Surveillance decisions will need to reflect variant position and clinical context
The management implications are immediate. Germline RNF43 remains a colorectal cancer predisposition gene, but the overall risk appears moderate rather than uniformly high. Variant position appears to matter, with stronger evidence for pathogenicity in N-terminal germline alterations. For C-terminal germline findings, the absence of increased risk in this dataset argues for caution before overcalling clinical significance, even while weak effects cannot be fully excluded.
In a genetics clinic, that means the colonoscopic phenotype, family history, and exact variant location all need to be weighed together. A carrier with an N-terminal truncating variant and early-onset disease in the family should not be managed as if they carry an incidental finding. A carrier with a C-terminal change and no polyp burden is a different case altogether. The study does not deliver a one-size-fits-all surveillance schedule, but it does redraw the risk map enough to change how results should be discussed.
Large population cohorts exposed what family studies missed
The strength of this work lies in its scale and its mix of datasets. By combining CORGI, the 100,000 Genomes Project, and UK Biobank, the investigators moved beyond the highly selected families that shaped earlier understanding of RNF43. That broader sampling exposed how often the expected phenotype is incomplete or absent, and it showed that germline and somatic mutation patterns do not mirror one another perfectly. The tumor set, meanwhile, helped explain why some C-terminal alterations behave as oncogenic drivers in the somatic setting even when inherited counterparts do not seem to raise risk in the same way.
This is a useful correction to an earlier, family-driven narrative. It suggests a genuine predisposition gene with incomplete penetrance, positional effects within the coding sequence, and cooperation from other Wnt-pathway lesions during tumor evolution. The study does not eliminate uncertainty around weak-effect variants, especially in the C-terminal region, but it narrows the uncertainty enough to matter at the bedside and in the genetics laboratory. Future clinical interpretation of RNF43 will need to distinguish inherited susceptibility from tumor-acquired biology rather than collapsing the two into a single category.